Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background The survival rate of prostate cancer is relatively higher than other cancers, therefore, the health-related quality of life (HRQoL) becomes a critical issue for the patients. There are limited quality of life data evaluating the difference between androgen deprivation therapy and non-androgen deprivation therapy. Objective To evaluate the HRQoL among prostate cancer patients with androgen deprivation therapy and non-androgen deprivation therapy in an Asian population. Setting The study was conducted at the urology outpatient department in a medical center and a regional hospital in southern Taiwan. Methods We collected the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Prostate (QLQ-PR25) among prostate cancer patients with and without androgen deprivation therapy from December 2017 to June 2018. The androgen deprivation therapy subjects in this study were using goserelin, leuprolide, degarelix, bicalutamide, enzalutamide, cyproterone, and abiraterone. The non-androgen deprivation therapy subjects were only receiving radiation therapy or radical prostatectomy. To investigate the determinants of HRQoL between androgen deprivation therapy and non-androgen deprivation therapy, multiple linear regression was used. Main outcomes measures The scores of EORTC QLQ-C30 and QLQ-PR25. Results In total, 182 subjects participated in the study of which 116 (63.74%) were in androgen deprivation therapy user group with a mean age (± SD, standard deviation) of 75.94 years (± 8.31), and 66 (36.26%) subjects were in non-androgen deprivation therapy user group with a mean age of 70.6 years (± 7.1). androgen deprivation therapy users’ quality of life was significantly lower than non-androgen deprivation therapy users (72.1 ± 19.3 vs. 77.8 ± 16.6, p = 0.0493). Conclusions The quality of life of patients with all-stages prostate cancer differs significantly between androgen deprivation therapy users and non-androgen deprivation therapy users. The HRQoL for androgen deprivation therapy users is worse than for the non-androgen deprivation therapy users. Additionally, the symptoms are the key determinants of the quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ministry of Health and Welfare. Death statistics annual report. 2017. https://www.mohw.gov.tw/lp-3961-2.html. Accessed 23 July 2018.

  2. Ministry of Health and Welfare. 2015 Taiwan Cancer Registry. https://www.hpa.gov.tw/EngPages/Detail.aspx?nodeid=1061&pid=6071. Accessed 29 Jan 2015.

  3. National Cancer Institute. Cancer stat facts: prostate cancer. 2016; https://seer.cancer.gov/statfacts/html/prost.html (2018). Accessed 12 Jan 2018.

  4. Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int J Urol. 2010;17(2):125–38.

    Article  PubMed  Google Scholar 

  5. Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, et al. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA. 2017;317(11):1141–50.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Namiki S, Kwan L, Kagawa-Singer M, Tochigi T, Ioritani N, Terai A, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis. 2008;11(3):298–302.

    Article  CAS  PubMed  Google Scholar 

  7. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(2 Suppl 3):73–81.

    CAS  PubMed  Google Scholar 

  8. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. J Comp Eff Res. 2013;2(4):445–60.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Shields AL, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, et al. Patient-Reported Outcomes in Oncology Drug Labeling in the United States: A Framework for Navigating Early Challenges. Am Health Drug Benefits. 2016;9(4):188–97.

    PubMed  PubMed Central  Google Scholar 

  10. Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19(1):19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Adamowicz K. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. Qual Life Res. 2017;26(4):813–22.

    Article  PubMed  Google Scholar 

  12. Osoba D. Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol. 2011;3(2):57–71.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Hino A, Tanaka N, et al. Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. UQual Life Res. 2019. https://doi.org/10.1007/s11136-019-02184-y.

    Article  Google Scholar 

  14. Lopez-Calderero I, Lopez-Fando L, Rios-Gonzalez E, Maisonobe P, Hernández-Yuste E, Sarmiento-Jordán M, et al. Impact of locally advanced or metastatic prostate cancer on the quality of life. Actas Urol. Esp. 2017;41(6):368–75.

    Article  CAS  PubMed  Google Scholar 

  15. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. The New England journal of medicine. 2016;375(15):1425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hashine K, Azuma K, Koizumi T, Sumiyoshi Y. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy. Int J Clin Oncol. 2005;10(1):45–50.

    Article  PubMed  Google Scholar 

  17. Chie W-C, Yu C-C, Yu H-J. Reliability and validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urol Sci. 2010;21(3):118–25.

    Article  Google Scholar 

  18. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual (3rd edition). European Organisation for Research and Treatment of Cancer; 2001.

  19. Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014;32(13):1324–30.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Health Promotion Administration Ministry of Health and Welfare Taiwan. Cancer registry annual report, 2015 Taiwan. https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=8084. Accessed 27 Dec 2017.

  21. National Health Research Institutes. Guideline for clinical diagnosis and treatment of prostate cancer. 2010; 2010:120.

  22. National Comprehensive Cancer Network. National Cancer Institute Cancer Stat Facts: Prostate Cancer (Version 2.2017). 2017; https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 8 Jan 2018.

  23. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753–60.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bergius S, Torvinen S, Muhonen T, Roine RP, Sintonen H, Taari K. Health-related quality of life among prostate cancer patients: real-life situation at the beginning of treatment. Scand J Urol. 2017;51(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  25. Mendez LC, Raman S, Wan BA, da Silva JLP, Moraes FY, Lima KMLB, et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort. Ann Palliat Med. 2017;6(Suppl 1):S65–s70.

    Article  PubMed  Google Scholar 

  26. Drummond FJ, Kinnear H, O’Leary E, Donnelly, Gavin A, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9(2):361–72.

    Article  PubMed  Google Scholar 

  27. Bach P, Doring T, Gesenberg A, Mohring C, Goepel M. Quality of life of patients after retropubic prostatectomy—pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. Health Qual Life Outcomes. 2011;9:93.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Adam S, Feller A, Rohrmann S, Arndt V. Health-related quality of life among long-term (>/=5 years) prostate cancer survivors by primary intervention: a systematic review. Health Qual Life Outcomes. 2018;16(1):22.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017;18(9):1192–201.

    Article  PubMed  Google Scholar 

  30. Adam S, Feller A, Rohrmann S, Arndt V. Health-related quality of life among long-term (>/=5 years) prostate cancer survivors by primary intervention: a systematic review. Health Qual Life Outcomes. 2018;16(1):22.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Lehto US, Tenhola H, Taari K, Aromaa A. Patients’ perceptions of the negative effects following different prostate cancer treatments and the impact on psychological well-being: a nationwide survey. Br J Cancer. 2017;116(7):864–73.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hung HY, Wu LM, Chen KP. Determinants of quality of life in lung cancer patients. J Nurs Scholarsh. 2018;50(3):257–64.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank the Center for Drug Evaluation and Ministry of Health and Welfare, Taiwan for supporting the program, and all the physicians who participated in this study. We also want to thank Dr. Tsu-Ming Chien for assistance in the writing of the study protocol.

Funding

This work was supported by a grant from the Center for Drug Evaluation and Ministry of Health and Welfare, Taiwan for supporting the program (RC1051116 and MOHW107-TDU-M-212-134005).

Author information

Authors and Affiliations

  1. Master Program in Clinical Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC

    Yu-Ting Huang & Chung-Yu Chen

  2. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC

    Ching‐Chia Li, Yii-Her Chou & Hung‐Lung Ke

  3. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC

    Ching‐Chia Li & Hung‐Lung Ke

  4. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC

    Hung‐Lung Ke

  5. Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC

    Chung-Yu Chen

  6. Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC

    Chung-Yu Chen

Authors
  1. Yu-Ting Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ching‐Chia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yii-Her Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hung‐Lung Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chung-Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chung-Yu Chen.

Ethics declarations

Conflicts of interest

The authors have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 33 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, YT., Li, C., Chou, YH. et al. Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study. Int J Clin Pharm 41, 993–1003 (2019). https://doi.org/10.1007/s11096-019-00854-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00854-y

Keywords

Search

Navigation